Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: A prospective, parallel, open-label, two-year extension study

Stefano Palomba, Francesco Manguso, Francesco Orio, Tiziana Russo, Rosamaria Oppedisano, Angela Sacchinelli, Angela Falbo, Achille Tolino, Fulvio Zullo, Pasquale Mastrantonio

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: To evaluate long-term efficacy of risedronate in osteoporotic postmenopausal patients with inflammatory bowel disease (IBD). Design: A prospective, parallel, open-label, 2-year extension study of a randomized, double-blind, 1-year clinical trial. Eighty-one osteoporotic postmenopausal women with IBD were treated with risedronate (n = 40) or placebo (n = 41). Bone mineral density (BMD), biochemical bone turnover markers, and vertebral and nonvertebral fractures were assessed throughout the study. Data were analyzed using the intent-to-treat principle. Results: Significant (P

Original languageEnglish
Pages (from-to)730-736
Number of pages7
JournalMenopause
Volume15
Issue number4
DOIs
Publication statusPublished - Jul 2008

Keywords

  • Bone fractures
  • Inflammatory bowel disease
  • Osteoporosis
  • Postmenopause
  • Risedronate

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Fingerprint Dive into the research topics of 'Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: A prospective, parallel, open-label, two-year extension study'. Together they form a unique fingerprint.

Cite this